Skip to search formSkip to main contentSkip to account menu

D07001-F4

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
330 First-in-man study of gemcitabine hydrochloride oral formulation (D07001-F4) in patients with malignant tumors
2015
2015
An open-label, exploratory, limited dose escalation study to evaluate the pharmacokinetics, safety and tolerability of gemcitabine hydrochloride oral formulation in subjects with malignant tumors.
e13537 Background: This open-label, phase 0, dose-escalation study of 3 successive cohorts was conducted to determine and… 
2014
2014
Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.
TPS2631^ Background: Gemcitabine HCl is a nucleoside analogue that exhibits antitumor activity and is approved for IV use in the… 
2014
2014
34 Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphoma
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)